Back to Search
Start Over
651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors
- Source :
- Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
- Publication Year :
- 2023
- Publisher :
- BMJ Publishing Group, 2023.
- Subjects :
- Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 11
- Issue :
- Suppl 1
- Database :
- Directory of Open Access Journals
- Journal :
- Journal for ImmunoTherapy of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.7b62f76ff37b4f64b88e92009cae8e48
- Document Type :
- article
- Full Text :
- https://doi.org/10.1136/jitc-2023-SITC2023.0651